Genesee Capital Advisors, LLC Chemo Centryx, Inc. Transaction History

Genesee Capital Advisors, LLC

$203 Million
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Jul 20, 2021	SELL	$9.59 - $50.88 $349,958 - $1.86 Million	-36,492 Closed	0 $0
Q1 2021 Apr 16, 2021	BUY	$49.53 - $68.4 $411,891 - $568,814	8,316 Added 29.51%	36,492 $1.87 Million
Q4 2020 Jan 19, 2021	BUY	$47.25 - $65.16 $14,411 - $19,873	305 Added 1.09%	28,176 $1.74 Million
Q3 2020 Oct 29, 2020	BUY	$46.35 - $61.69 $10,845 - $14,435	234 Added 0.85%	27,871 $1.53 Million
Q2 2020 Jul 20, 2020	SELL	$38.58 - $65.07 $157,637 - $265,876	-4,086 Reduced 12.88%	27,637 $1.59 Million
Q1 2020 Apr 16, 2020	BUY	$32.73 - $50.78 $1.04 Million - $1.61 Million	31,723 New	31,723 $1.27 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Genesee Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Genesee Capital Advisors, LLC with notifications on news.